menu
    • menu
    [{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"University College Cork","sponsor":"Health Service Executive","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"University College Cork","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College Cork \/ Health Service Executive","highestDevelopmentStatusID":"1","companyTruncated":"University College Cork \/ Health Service Executive"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"The Affiliated Hospital of Qingdao University | Nakhia Impex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex"},{"orgOrder":0,"company":"Orthox","sponsor":"Parkwalk","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"Fibroin","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Orthox","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Orthox \/ Parkwalk","highestDevelopmentStatusID":"1","companyTruncated":"Orthox \/ Parkwalk"},{"orgOrder":0,"company":"Green Cross Wellbeing","sponsor":"Chung-Ang University Hosptial, Chung-Ang University College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Human Placenta Hydrolysate","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Green Cross Wellbeing","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Green Cross Wellbeing \/ Chung-Ang University Hosptial, Chung-Ang University College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Green Cross Wellbeing \/ Chung-Ang University Hosptial, Chung-Ang University College of Medicine"},{"orgOrder":0,"company":"Alternativa International S.A","sponsor":"Artialis","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Myostim","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Alternativa International S.A","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alternativa International S.A \/ Artialis","highestDevelopmentStatusID":"1","companyTruncated":"Alternativa International S.A \/ Artialis"},{"orgOrder":0,"company":"NutraHeal","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutraheal","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"NutraHeal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NutraHeal \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NutraHeal \/ Undisclosed"},{"orgOrder":0,"company":"Qianfoshan Hospital","sponsor":"Shandong Qilu Stem Cells Engineering Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Umbilical Cord Blood Mononuclear Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Qianfoshan Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qianfoshan Hospital \/ Shandong Qilu Stem Cells Engineering Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Qianfoshan Hospital \/ Shandong Qilu Stem Cells Engineering Co., Ltd."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Xr Recovery Supplement","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Royal College of Surgeons, Ireland","sponsor":"Health Service Executive, Ireland","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"IRELAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Royal College of Surgeons, Ireland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal College of Surgeons, Ireland \/ Health Service Executive, Ireland","highestDevelopmentStatusID":"1","companyTruncated":"Royal College of Surgeons, Ireland \/ Health Service Executive, Ireland"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Royal College of Surgeons, Ireland

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Royal College of Surgeons, Ireland

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Health Service Executive, Ireland

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Frailty Intervention in Postoperative Hip Fracture Inpatients

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Hip Fractures.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 18, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Health Service Executive, Ireland

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NYU Langone Health

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            NYU Langone Health

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xr Recovery Supplement

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nutritional Supplementation in Geriatric Hip Fractures

                            Details : Xr Recovery Supplement is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hip Fractures.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            January 14, 2025

                            Lead Product(s) : Xr Recovery Supplement

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dove Medical Press

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Dove Medical Press

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : The Affiliated Hospital of Qingdao University | Nakhia Impex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study of Freshly Manufactured 35kDa Hyaluronan Fragment in the Treatment of Pain

                            Details : Sodium Hyaluronate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Shoulder Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : The Affiliated Hospital of Qingdao University | Nakhia Impex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Green Cross Wellbeing

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Green Cross Wellbeing

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Placenta Hydrolysate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Chung-Ang University Hosptial, Chung-Ang University College of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administe...

                            Details : Laennec (Human Placenta Hydrolysate) is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Shoulder Impingement Syndrome.

                            Product Name : Laennec

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : Human Placenta Hydrolysate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Chung-Ang University Hosptial, Chung-Ang University College of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NutraHeal

                            Country arrow
                            BioJapan
                            Not Confirmed

                            NutraHeal

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nutraheal

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nutritional Supplements and Foot Surgery

                            Details : Nutraheal is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Foot Injuries and Disorders.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            August 30, 2022

                            Lead Product(s) : Nutraheal

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Regenexx

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Platelet Rich Plasma

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial for Treating Painful Degenerative Disc Disease

                            Details : Platelet Rich Plasma is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Intervertebral Disc Degeneration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 18, 2022

                            Lead Product(s) : Platelet Rich Plasma

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Orthox

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed

                            Orthox

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibroin

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Parkwalk

                            Deal Size : $12.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Orthox Closes $12.5m Series A Financing for Clinical Trials of Knee Cartilage Repair FibroFix™ Product Platf...

                            Details : The financing will support further clinical trials of its lead product, FibroFix™, at Southmead Hospital Bristol, UK and in Budapest, Hungary. FibroFix is unique in emulating the functional properties of cartilage while also facilitating rapid tissue r...

                            Product Name : FibroFix

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : Fibroin

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Parkwalk

                            Deal Size : $12.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University College Cork

                            Country arrow
                            BioJapan
                            Not Confirmed

                            University College Cork

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Health Service Executive

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PENG Versus Femoral Nerve Block in Neck of Femur Fracture

                            Details : Lidocaine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Femoral Fractures.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 12, 2021

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Health Service Executive

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Qianfoshan Hospital

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Qianfoshan Hospital

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Blood Mononuclear Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Shandong Qilu Stem Cells Engineering Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Hea...

                            Details : Umbilical Cord Blood Mononuclear Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Fractures, Ununited.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 09, 2021

                            Lead Product(s) : Umbilical Cord Blood Mononuclear Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Shandong Qilu Stem Cells Engineering Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alternativa International S.A

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Alternativa International S.A

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Myostim

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Artialis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tolerance, Efficacy, revAlidation, Myostim

                            Details : Myostim is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Anterior Cruciate Ligament Injuries.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 28, 2020

                            Lead Product(s) : Myostim

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Artialis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth